Table 1 Patient details and infused unit... | American Society of Hematology

Table 1

Patient details and infused unit characteristics

Patient no.	Transplantation type*	Age, y	Weight, kg	Disease	Status	TNC × 10⁷/kg			CD34⁺ × 10⁵/kg			CD3⁺ × 10⁶/kg			Days to engraftment	Dominant unit
Patient no.	Transplantation type*	Age, y	Weight, kg	Disease	Status	Unit 1	Unit 2	Total	Unit 1	Unit 2	Total	Unit 1	Unit 2	Total	Days to engraftment	Dominant unit
1	MUU	29	103	AML	CR2	1.2	1	2.2	1.3	0.5	1.8	4.7	2.7	7.4	45	Mixed
2	MUU	28	53	ALL	CR1	2.1	1.4	3.5	0.9	2.6	3.5	5.6	4.3	9.9	23	2
3	MUU	24	78	CML	CP1	2.2	2	4.2	1.3	0.9	2.2	8.3	7.9	16.2	44	2
4	MUU	18	68	MDS		1.5	1.6	3.1	1.1	2.5	3.6	5	5	10	30	1
5	MUU	39	64	AML	CR2	3.6	1.7	5.3	3.8	1	4.8	11	5	16	16	1
6	RIC	56	100	AML	CR2	3.1	1.5	4.6	6.4	1.1	7.5	7.6	6	13.6	7‡	1
7	RIC	67	83	AML	CR1	2.3	1.8	4.1	1.6	1.3	2.9	6.8	4.2	11	8‡	2
8	RIC	64	88	AML	CR2	1.7	1.4	3.1	0.7	0.9	1.6	3.6	3.6	7.2	6‡	1
9	RIC	62	80	AML/MDS	MDS	2.2	1.9	4.1	2.8	0.9	3.7	6.4	5.5	11.9	Death	2
10	RIC	46	57	CLL	PR	1.9	1.8	3.7	0.5	0.7	1.2	5.5	4.8	10.3	24	Mixed
11	MUE	30	72	AML	CR2	2.7	0.6	3.3	3.4	11.2	14.6	4.2	NA†	4.2	13§	1
12	MUE	29	79	ALL	CR1	1.5	3.2	4.7	0.6	84	84.6	3	NA†	3	NA	Rejection
13	MUE	42	66	AML	CR3	3	2.3	5.3	2.6	29	31.6	7	NA†	7	21	1
14	MUE	26	78	AML/ALL	CR1	1.9	9.1	11	1.6	97	98.6	3.6	NA†	3.6	7§	Mixed

Patient no.	Transplantation type*	Age, y	Weight, kg	Disease	Status	TNC × 10⁷/kg			CD34⁺ × 10⁵/kg			CD3⁺ × 10⁶/kg			Days to engraftment	Dominant unit
Patient no.	Transplantation type*	Age, y	Weight, kg	Disease	Status	Unit 1	Unit 2	Total	Unit 1	Unit 2	Total	Unit 1	Unit 2	Total	Days to engraftment	Dominant unit
1	MUU	29	103	AML	CR2	1.2	1	2.2	1.3	0.5	1.8	4.7	2.7	7.4	45	Mixed
2	MUU	28	53	ALL	CR1	2.1	1.4	3.5	0.9	2.6	3.5	5.6	4.3	9.9	23	2
3	MUU	24	78	CML	CP1	2.2	2	4.2	1.3	0.9	2.2	8.3	7.9	16.2	44	2
4	MUU	18	68	MDS		1.5	1.6	3.1	1.1	2.5	3.6	5	5	10	30	1
5	MUU	39	64	AML	CR2	3.6	1.7	5.3	3.8	1	4.8	11	5	16	16	1
6	RIC	56	100	AML	CR2	3.1	1.5	4.6	6.4	1.1	7.5	7.6	6	13.6	7‡	1
7	RIC	67	83	AML	CR1	2.3	1.8	4.1	1.6	1.3	2.9	6.8	4.2	11	8‡	2
8	RIC	64	88	AML	CR2	1.7	1.4	3.1	0.7	0.9	1.6	3.6	3.6	7.2	6‡	1
9	RIC	62	80	AML/MDS	MDS	2.2	1.9	4.1	2.8	0.9	3.7	6.4	5.5	11.9	Death	2
10	RIC	46	57	CLL	PR	1.9	1.8	3.7	0.5	0.7	1.2	5.5	4.8	10.3	24	Mixed
11	MUE	30	72	AML	CR2	2.7	0.6	3.3	3.4	11.2	14.6	4.2	NA†	4.2	13§	1
12	MUE	29	79	ALL	CR1	1.5	3.2	4.7	0.6	84	84.6	3	NA†	3	NA	Rejection
13	MUE	42	66	AML	CR3	3	2.3	5.3	2.6	29	31.6	7	NA†	7	21	1
14	MUE	26	78	AML/ALL	CR1	1.9	9.1	11	1.6	97	98.6	3.6	NA†	3.6	7§	Mixed

AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; TNC, total nucleated cells; and NA, not applicable.

Transplantation types are MUU (myeloablative, both units unmanipulated), RIC (reduced-intensity conditioning), and MUE (myeloablative, unmanipulated and expanded).

†

Unit was CD34⁺ selected and ex vivo expanded. The negative fraction after CD34⁺ selection was not added back at the time of transplantation, and no T cells from this unit were infused.

‡

Initial neutrophil recovery was the result of transient autologous recovery of the myeloid (CD33⁺) lineage.

Initial neutrophil recovery was the result of transient production of the myeloid (CD33⁺) lineage from the CD34⁺ selected/expanded cord blood unit.

View Large

This Feature Is Available To Subscribers Only